Fibroblast activation protein (FAP), which is overexpressed in cancer-associated fibroblasts (CAFs), represents a promising target for cancer diagnosis and therapy. Hypoxia is a common feature of solid tumors. A bivalent agent, DOTA-NI-FAPI-04 (), was developed by incorporating hypoxia-sensitive nitroimidazole (NI) into the FAP-targeting agent FAPI-04. Compound exhibited a strong FAP binding affinity with an IC of 7.44 nM. Radiolabeled [Ga]Ga- and [Lu]Lu- demonstrated enhanced cell uptake. positron emission tomography/computed tomography (PET/CT) imaging showed that [Ga]Ga- displayed significantly higher specific uptake and retention in U87MG tumor-bearing mice compared to [Ga]Ga-FAPI-04 (SUV: 7.87 vs 1.99% ID/mL at 120 min). Biodistribution studies confirmed superior tumor uptake of [Ga]Ga- (48.15 vs 5.72% ID/g at 120 min). Similarly, [Lu]Lu- exhibited higher tumor uptake than [Lu]Lu-FAPI-04 (50.75 vs 20.48% ID/g at 120 min). These preliminary results suggest that a nitroimidazole-containing bivalent-targeting agent, [Ga]Ga/[Lu]Lu-, is a promising candidate for tumor theranostics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.jmedchem.4c02015 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!